NCT03635814Unknown2 期
Multi-center, Randomized, Double-blind, Dose-finding, Phase 2a Clinical Trial to Evaluate the Effecacy and Safety of YD312 Tablet in Patients With Diabetic Macular Edema
YD Global Life Science Co., Ltd.20 个研究点 分布在 2 个国家目标入组 100 人开始时间: 2017年10月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 100
- 试验地点
- 20
- 主要终点
- Change in ETDRS BCVA latter score from baseline at Week 12 ( ETDRS chart reading at least 3 letters)
研究概览
简要总结
This study objectives is to evaluate the efficacy of YD312 to improve visual acuity in patients with diabetic macular edema (DME) compared to placebo and determine optimal dose of phase 2b study.
详细描述
These study results present the possibility that imatinib can be used as a new DME inhibiting agent by involving VEGF-independent ocular angiogenesis, not action points of existing agents, in effectively inhibiting excessive vascular angiogenesis observed in oxygen-induced retinopathy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Screening Inclusion Criteria
- •Study subjects must be eligible for the following criteria at screening:
- •Subject who is male or female ≥ 19 years of age
- •Subject who has a diagnosis of Type 1 or 2 diabetes
- •Subject who has study eye with definite retinal thickening due to diabetic macular edema involving the center of the macula
- •Subject who has voluntarily signed an informed consent form
- •Randomization Inclusion Criteria
- •Study eye must be eligible for the following criteria at randomization:
- •Subject who has study eye with central subfield thickness (CST) of ≥ 300 μm on optical coherence tomography (OCT)
- •Subject who has study eye with an early treatment diabetic retinopathy study (ETDRS) best-corrected visual acuity (BCVA) letter score ranging from 39 to 78, inclusive (approximate Snellen equivalent of 20/32 - 20/160)
排除标准
- •Subject who has study eye with any of the following criteria:
- •Subject whose primary cause of macular edema is non-diabetic disease/condition (e.g., cataract extraction, vitreomacular interface abnormalities)
- •Subject who is expected to have no improvement of decreased visual acuity in the opinion of investigator, even if macular edema is resolved (e.g., foveal atrophy, abnormal pigmentation, dense subfoveal hard exudate)
- •Subject who has proliferative diabetic retinopathy.
- •Subject who took the following within 3 months before randomization
- •① Focal/grid laser photocoagulation
- •② Intravitreal/circumbulbar corticosteroid, anti-VEGF and pro-VEGF (but, no wash-out period is required for the corticosteroid eyedrops)
- •Subject who took panretinal photocoagulation (PRP) or intravitreal dexamethasone implant within 6 months before randomization
- •Subject who has a history of vitrectomy
- •Subject who took major ophthalmic surgeries (all intraocular surgeries including cataract extraction and scleral buckle) within 6 months before randomization
- •Subject who had systemic treatment of corticosteroid or anti-VEGF within 3 months before randomization.
- •Subject who administered vaccinium myrtillus extract or dobesilate calcium within 2 weeks before randomization
- •Subject who is suspected to require administration/treatment of drug/procedure that may affect the efficacy evaluation before the participation of clinical trial or during clinical trial (refer to '10.4 Combination Therapy and Contraindication').
- •Subject who has the following illness or abnormal laboratory test values:
- •Subject who has a hypersensitivity to any excipients of the investigational product or similar class of drug and ingredient
- •Subject who has uncontrolled hypertension (SBP > 160 mmHg or DBP >100 mmHg)
- •Subject who has uncontrolled diabetes (HbA1c > 10.0%)
- •Subject who has uncontrolled glaucoma in either eye (intraocular pressure (IOP) > 24 mmHg on medication or according to the investigator's judgment)
- •ANC < 1.5 × 109/L
- •Platelet < 125 × 109/L
- •Total bilirubin > 1.5 × ULN
- •AST or ALT > 2 × ULN
- •Clcr* < 40 mL/min
- •* Clcr (Cockcroft-Gault formula)
- •= [(140 - age) x weight(kg) (x 0.85 for females)] / [72 x serum creatinine (Scr) (mg/dL)]
- •Severe heart failure (NYHA class III/IV)
- •Malignant tumor within 5 years before randomization
- •Subject who is known to be HIV positive, is active hepatitis B patient or carrier, or is hepatitis C patient
- •Ocular inflammatory diseases such as uveitis, conjunctivitis, and blepharitis in either eye. However, the participation of subject in this study is considered at the discretion of investigator.
- •Unstable angina, myocardial infarction, transient ischemic attack, cerebral infarction, coronary artery bypass surgery, or transluminal coronary angioplasty within 6 months before screening
- •Pregnant woman, lactating woman, or female or male subject of childbearing potential
- •*hormonal contraceptives, intrauterne contraceptive device, sterilization of spouse (e.g., vasectomy, tubal ligation), double-barrier method (e.g., combinational use of spermicides and condoms, diaphragm, contraceptive sponge, of FemCap)
- •Subject who took administraion/procedure of other investigational products or medical devices within longer period between 30 days before screening or over 5time half-life.
- •Subject, at the discretion of the investigator, who is unsuitable to participate in the study.
研究组 & 干预措施
YD312 drug treatment
Experimental
From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
干预措施: YD312 50mg (Drug)
YD312 drug treatment
Experimental
From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
干预措施: YD312 150mg (Drug)
YD312 drug treatment
Experimental
From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
干预措施: YD312 350mg (Drug)
YD312 placebo drug treatment
Placebo Comparator
From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
干预措施: Placebo (Drug)
结局指标
主要结局
Change in ETDRS BCVA latter score from baseline at Week 12 ( ETDRS chart reading at least 3 letters)
时间窗: BCVA ERDRS measure at V1(screening), V2(baseline,week0), V3(week4), V4(week8), V5(week12)
次要结局
- Change in CST from baseline at Weeks 4, 8, and 12(BCVA ERDRS measure at V1(screening), V2(baseline,week0), V3(week4), V4(week8), V5(week12))
- Improvement or worsening rate of ETDRS BCVA from baseline at Weeks 4, 8, and 12(BCVA ERDRS measure at V1(screening), V2(baseline,week0), V3(week4), V4(week8), V5(week12))
- Change in ETDRS BCVA latter score from baseline at Weeks 4 and 8(BCVA ERDRS measure at V1(screening), V2(baseline,week0), V3(week4), V4(week8), V5(week12))
研究者
研究点 (20)
Loading locations...
相似试验
终止
2 期
Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular EdemaDiabetes ComplicationsDiabetic RetinopathyNCT00701181Quark Pharmaceuticals184
已完成
3 期
Clinical Study to Evaluate the Safety and Performance of the Intraocular Lens (Investigational Device Development Code: SP2Y-GMF) After Implantation.D002386CataractJPRN-jRCT2072210002Eguchi Shuichiro64
已完成
3 期
An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult PopulationsOcular RednessEye IrritationNCT06538662Alcon Research283
招募中
3 期
Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle GlaucomaGlaucoma, Open-AngleNCT05710198Omikron Italia S.r.l.1,000
已完成
2 期
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)Chronic Graft-versus-host DiseaseNCT02040623Rigel Pharmaceuticals35